Last reviewed: May 30, 2026
Last updated: May 30, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
Yes, GLP-1 medication shortages have largely resolved as of 2024, expanding patient access to multiple formulations and dosing options. Supply chain normalization, combined with new compounded alternatives and branded products, has created a more diverse treatment ecosystem requiring informed decision-making.
This expanded landscape makes personalization increasingly important. Understanding your baseline biomarkers and genetic context in peptide metabolism can help support conversations with your provider about which GLP-1 approach may align best with your individual physiology and health goals.
Start your GLP-1 program with PlexusDx
One all-inclusive price covers your online provider visit, prescription, compounded medication, and shipping — no membership, no hidden fees. Complete a short intake and a licensed provider takes it from there.
Start your intake →
How GLP-1 Supply Has Stabilized Since 2023
In 2023, demand for semaglutide and tirzepatide far exceeded supply due to unexpected adoption for weight management beyond diabetes. FDA manufacturing coordination, expanded production capacity, and regulatory approval of compounded alternatives significantly improved availability by late 2023 through 2024.
Current supply includes branded injectables (Ozempic, Mounjaro), oral formulations (Rybelsus, Zepbound), and compounded options from licensed 503A pharmacies. This multi-pathway availability means patients now have realistic access but must evaluate options based on medical history, preferences, and clinical evidence rather than availability alone.
The Compounded vs. Branded Treatment Framework
Both compounded and branded GLP-1 medications work through similar mechanisms but differ in manufacturing oversight, cost, and customization. Understanding these distinctions supports informed provider conversations about which pathway aligns with your clinical needs and circumstances.
| Treatment Path |
Key Characteristics |
Cost Range (Typical) |
Clinical Context |
| Compounded Semaglutide |
From licensed 503A pharmacy; dosing flexibility; lower cost |
$149/mo |
For patients prioritizing cost, customized dosing, or who cannot access branded options |
| Compounded Tirzepatide |
Dual GLP-1/GIP mechanism; 503A pharmacy; customizable strength |
$249/mo |
For those exploring dual-mechanism peptide therapy; may offer different metabolic profile |
| Branded Semaglutide (Wegovy/Ozempic) |
FDA-approved; standardized dosing; established safety database |
$900–$1,300/month retail |
For patients with insurance coverage or who prefer established branded formulations |
| Branded Tirzepatide (Zepbound/Mounjaro) |
FDA-approved dual mechanism; fixed dosing; extensive clinical trials |
$700–$1,200/month retail |
For those exploring GLP-1/GIP pathway with full regulatory approval history |
Genetic Predispositions That Inform Treatment Selection
The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to GLP-1 medications or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.
PlexusDx Precision Peptide Genetic Test examines key variants including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313. These predispositions may help clarify whether you carry genetic markers associated with stronger GLP-1 pathway sensitivity, informing more targeted treatment conversations with your provider.
Safety, Eligibility, and Provider-Guided Decision-Making
GLP-1 medications are not appropriate for everyone. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, active pancreatitis, severe diabetic retinopathy, and certain pregnancy circumstances. A qualified healthcare provider must evaluate your complete medical history before recommending any formulation.
The expanded treatment landscape requires thoughtful provider partnership. Discussing your baseline metabolic biomarkers, genetic context, medication history, and health goals helps your provider select the formulation and dose most likely to be effective and tolerable for your specific situation. Neither genetic predisposition nor availability alone should drive treatment selection.
How PlexusDx Supports a More Personalized Approach
PlexusDx recognizes that GLP-1 treatment success depends not only on medication availability but also on alignment between the chosen formulation and your individual metabolic pathway. Our Precision Peptide Genetic Test may help provide context about your predispositions in key peptide signaling genes, supporting more informed discussions with your provider about which GLP-1 approach may be most suitable for your physiology.
The Precision Peptide Genetic Test reveals predispositions in GIPR, FTO, and MC4R pathways—genes that influence how your body responds to GLP-1 and GIP signaling. This information should be interpreted with a qualified healthcare provider, as genetic predisposition does not guarantee medication response or outcome. Instead, it adds a layer of personalization to the clinical conversation.
By combining genetic insights with biomarker assessment and medical history, you and your provider can make more targeted decisions about whether compounded semaglutide, compounded tirzepatide, or another GLP-1 pathway is most aligned with your health needs. This precision-wellness approach transforms the expanded treatment landscape from overwhelming choice into informed personalization.
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.
Frequently Asked Questions
Does this article say the GLP-1 shortage is actually over?
It says shortages have largely resolved, crediting FDA manufacturing coordination, expanded production capacity, and the growth of compounded alternatives. That claim is anchored to a specific point in time in the article rather than to current conditions, so supply status is worth confirming with a pharmacy or prescriber before planning around it. The post's broader point is that availability is no longer the main constraint.
What does the article blame for the original squeeze on supply?
Demand for semaglutide and tirzepatide that far outran supply, driven by adoption for weight management well beyond the diabetes population these products were first built around. The article frames the recovery as a combination of manufacturing coordination and expanded capacity rather than demand falling off. It presents the result as a more diverse treatment ecosystem instead of a single dominant option.
What separates the compounded and branded paths in the article's comparison table?
Three things: manufacturing oversight, cost, and customization. The table describes compounded preparations from a licensed 503A pharmacy as offering dosing flexibility at lower cost, and branded products as FDA-approved with standardized dosing and an established safety database. It also gives a retail cost range for the branded columns, which is why the two paths are not priced on the same basis.
Which contraindications does the post apply across every formulation?
A personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, active pancreatitis, severe diabetic retinopathy, and certain pregnancy circumstances. The article states these apply regardless of which pathway someone is considering. It insists a qualified provider evaluate the complete medical history before recommending any formulation, branded or compounded.
Should availability drive which option someone ends up on?
The article says no, twice. Early on it argues that with supply restored, patients should evaluate options based on medical history, preferences, and clinical evidence rather than what happens to be in stock. Near the end it repeats that neither availability nor any single piece of background information should drive treatment selection on its own. That decision sits with the provider.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Safely Stop Ozempic: Clinical Discontinuation Guidelines
Duration of Ozempic for Weight Loss